Mumbai, July 31 -- The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.

Profit before exceptional items and tax stood at Rs 3,990.8 crore in Q1 FY26, up 16.6% YoY.

In Q1 FY26, EBITDA stood at Rs 4,301.7 crore (including other operating revenues), up 19.2%, with resulting EBITDA margin of 31.1%.

India formulations sales were Rs 4,721.1 crore for Q1 FY26, a growth of 13.9% over Q1 FY25 and accounted for 34.2% of total consolidated sales for the quarter.

US formulation sales were $473 million for Q1 FY26, up 13.9% over Q1 FY25 and accounted for 29.3% of total consolidated sales for the quarter.

Global Innovative Medicines (formerly the specialty business) sales were $311 million for ...